Adenosine amine congener ameliorates cisplatin-induced hearing loss

Figure 2 The effect of adenosine amine congener on cisplatin-induced auditory brainstem responses threshold shifts. A: Auditory brainstem responses (ABR) thresholds before (baseline) and 7 d after cisplatin administration (final). Adenosine amine congener (ADAC) was co-applied with cisplatin during the second cycle (Regime 1); B: ADAC reduced ABR threshold shifts when administered concomitantly with the second cisplatin cycle; C: ABR thresholds before (baseline) and 7 d after cisplatin administration (final). ADAC was administered after the completion of cisplatin treatment (Regime 2); D: ADAC had no effect on cisplatin-induced threshold shifts when applied after the completion of cisplatin treatment. In the control group, injections of the vehicle solution were administered at the same intervals as ADAC. ABRs were measured in response to tone pips (4-24 kHz). Data are expressed as mean ± SE (n = 8). ^bP < 0.01 vs control group, one-way analysis of variance.